Loading...
XNAS
BMRA
Market cap6mUSD
Dec 05, Last price  
2.34USD
1D
1.61%
1Q
-14.91%
Jan 2017
1.74%
Name

Biomerica Inc

Chart & Performance

D1W1MN
XNAS:BMRA chart
P/E
P/S
1.26
EPS
Div Yield, %
Shrs. gr., 5y
-25.73%
Rev. gr., 5y
-4.52%
Revenues
5m
-1.92%
7,184,9925,748,3194,926,5054,934,7715,075,2224,899,3756,081,1316,472,9605,120,4514,962,3735,139,8165,791,6705,564,1855,200,6826,692,7117,199,02718,871,4095,339,0005,415,0005,311,000
Net income
-5m
L-16.81%
230,273536,8791,710,044354,180-331,455157,447548,435536,957-215,660-331,410-1,499,787-908,561-1,465,828-2,393,060-2,339,054-6,469,036-4,531,044-7,140,000-5,978,000-4,973,000
CFO
-4m
L-28.35%
-385,169463,708-194,595-101,999-236,980328,803147,4121,394,037-862,273-405,481-208,782-722,858-1,174,217-2,244,039-4,297,498-5,251,748-480,532-5,474,000-5,361,000-3,841,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Biomerica, Inc., a biomedical technology company, develops, patents, manufactures, and markets diagnostic and therapeutic products for the detection and/or treatment of medical conditions and diseases worldwide. The company's diagnostic test kits are used to analyze blood, urine, or fecal specimens from patients in the diagnosis of various diseases and other medical complications; or to measure the level of specific bacteria, hormones, antibodies, antigens, or other substances, which exist in the patient's body and stools or blood in extremely small concentrations. It primarily sells its products for gastrointestinal diseases, food intolerances, diabetes, and various esoteric tests at the physicians' offices and over-the-counter drugstores, and hospital/clinical laboratories. The company is also developing InFoods, an irritable bowel syndrome therapy technology and diagnostic-guided therapy; Helicobacter pylori products, as well as develops, tests, validates, and sells diagnostic products for COVID-19 infection. Biomerica, Inc. was incorporated in 1971 and is headquartered in Irvine, California.
IPO date
Mar 17, 1980
Employees
62
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑052024‑052023‑052022‑052021‑052020‑052019‑052018‑052017‑052016‑05
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT